G. Akabani

发表

Utilizing MRI information to estimate F18-FDG distributions in rat flank tumors

J. Bowsher, T. Turkington, L. Hedlund, 2004, IEEE Symposium Conference Record Nuclear Science 2004..

Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.

R. Coleman, A. Friedman, D. Bigner, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A dose constraint proposal for members of the public taking into account multi-unit nuclear power plants in Korea

G. Akabani, T. Kong, H. Kim, 2015 .

Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.

M. Berger, A. Friedman, D. Bigner, 2006, Neurosurgical focus.

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

R. Coleman, R. McLendon, A. Friedman, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiological Safety Concerns for the Accelerator Production of Diagnostic and Therapeutic Radionuclides in a University Setting

G. Akabani, T. M. Martin, 2012, Health physics.

An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation‐mediated bystander effects

M. Zalutsky, P. Welsh, W. Keith, 2004, The journal of gene medicine.

Microbial influences on hormesis, oncogenesis, and therapy: A review of the literature.

D. Saucier, G. Akabani, Ryan Clanton, 2015, Environmental research.

Estimates of beta absorbed fractions in small tissue volumes for selected radionuclides.

W. Bolch, G. Akabani, J. Poston, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.

R. Coleman, D. DeLong, R. McLendon, 2000, International journal of radiation oncology, biology, physics.

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

R. Coleman, R. McLendon, A. Friedman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

R. Coleman, R. McLendon, A. Friedman, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional Genomics Screening Utilizing Mutant Mouse Embryonic Stem Cells Identifies Novel Radiation-Response Genes

J. Sacchettini, T. Ioerger, D. Wallis, 2015, PloS one.

Rapid synthesis of 125I integrated gold nanoparticles for use in combined neoplasm imaging and targeted radionuclide therapy.

Arnulfo Gonzalez, G. Akabani, Ryan Clanton, 2018, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

R. Coleman, R. McLendon, A. Friedman, 2008, Neuro-oncology.

A Study of a Dose Constraint for Members of the Public Living Around Nuclear Power Plants in the United States

G. Akabani, T. Kong, J. Poston, 2018, Nuclear Technology.

A STUDY OF A DOSE CONSTRAINT FOR OCCUPATIONALLY EXPOSED WORKERS IN THE US NUCLEAR POWER PLANTS.

G. Akabani, T. Kong, J. Poston, 2018, Radiation protection dosimetry.

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

R. Coleman, R. McLendon, A. Friedman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.

M. Zalutsky, R. Larsen, O. Bruland, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.

D. Bigner, M. Zalutsky, G. Akabani, 2004, Nuclear medicine and biology.

Production of the alpha particle emitting radionuclide At-211 at the Texas A&M Cyclotron Institute

R. Tribble, M. Lenox, G. Akabani, 2011 .

Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.

W. Hawkins, M. Tempero, J. Baranowska-Kortylewicz, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Overcoming Barriers to Radiopharmaceutical Therapy: An Overview from the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy (RPT).

Daniel A. Jacobson, J. Humm, E. Moros, 2020, International journal of radiation oncology, biology, physics.

Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I‐radiolabeled antichondroitin proteoglycan sulfate Mel‐14 F(ab′)2

D. Bigner, J. Provenzale, H. Friedman, 2001, Cancer.

Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

R. McLendon, A. Friedman, D. Bigner, 2007, Nuclear medicine and biology.

Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.

J. Bowsher, K. Greer, R. Coleman, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.

R. McLendon, D. Bigner, M. Zalutsky, 1999, International journal of radiation oncology, biology, physics.

Wet harvesting of no-carrier-added 211At from an irradiated 209Bi target for radiopharmaceutical applications

M. Zalutsky, S. Carlin, G. Akabani, 2004 .

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.

J. Bowsher, R. Coleman, D. Bigner, 2004, Blood.

Phase 1 trial study of 131 I-labeled chimeric 81 C 6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

J. Bowsher, R. Coleman, D. Bigner, 2004 .

Dosimetry of 1311-Labeled81C6 Monoclonal Antibody Administered into Surgically Created Resection Cavities in Patients with Malignant Brain Tumors

D. Bigner, H. Friedman, M. Zalutsky, 2006 .

Wet harvesting of no-carrier-added 211At from an irradiated 209Bi target for radiopharmaceutical applications

M. Zalutsky, S. Carlin, G. Akabani, 2005 .

The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.

M. Zalutsky, R. Larsen, G. Akabani, 1998, Radiation research.

Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT.

R. Jaszczak, K. Greer, R. Coleman, 2007, Radiology.

Exposure of human osteosarcoma and bone marrow cells to tumour-targeted α-particles and γ-irradiation: analysis of cell survival and microdosimetry

D. Olsen, M. Zalutsky, R. Larsen, 2000 .

Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.

D. Olsen, M. Zalutsky, R. Larsen, 2000, International journal of radiation biology.

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy*

B. Wessels, J. Roeske, M. McDevitt, 2010, Journal of Nuclear Medicine.

Overview of the First NRG Oncology–National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy

J. Humm, R. Wahl, S. Mirzadeh, 2020, The Journal of Nuclear Medicine.

Comparative dosimetry of BEIR VI revisited.

A. James, G. Akabani, A. Birchall, 2004, Radiation protection dosimetry.

Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.

R. McLendon, M. Hanson, R. Coleman, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Annexe H. Absorbed Fractions for Alpha, Electron, and Beta Emissions

A. James, G. Akabani, A. Birchall, 1994 .

Annexe H. absorbed fractions for alpha, electron, and beta emissions

A. James, G. Akabani, A. Birchall, 1994 .

Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides.

G. Akabani, J. Poston, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Chemical Design of Both a Glutathione-Sensitive Dimeric Drug Guest and a Glucose-Derived Nanocarrier Host to Achieve Enhanced Osteosarcoma Lung Metastatic Anticancer Selectivity.

Yen-Nan Lin, K. Wooley, J. Smolen, 2018, Journal of the American Chemical Society.

Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components.

Y. Erdi, B. Wessels, A. Brill, 2000, Medical physics.

Radioimmunotherapy for Non-Hodgkin's Lymphoma.

D. Rizzieri, A. Rao, G. Akabani, 2005, Clinical medicine & research.

Microdosimetry of astatine-211 using histological images: application to bone marrow.

M. Zalutsky, G. Akabani, 1997, Radiation research.

Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

M. Berger, R. McLendon, A. Friedman, 2003, Journal of Neuro-Oncology.

Migration of human dendritic cells after injection in patients with metastatic malignancies.

R. Coleman, H. Lyerly, M. Morse, 1999, Cancer research.

Dosimetry of a (90)Y-hydroxide liquid brachytherapy treatment approach to canine osteosarcoma using PET/CT.

R. Wendt, Arnulfo Gonzalez, M. Lenox, 2015, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

R. Coleman, R. McLendon, A. Friedman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of cAMP-dependent Signaling in Receptor-recognized Forms of α2-Macroglobulin-induced Cellular Proliferation*

S. Pizzo, U. K. Misra, G. Akabani, 2002, The Journal of Biological Chemistry.

In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.

M. Zalutsky, S. Carlin, G. Akabani, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Control of seizures by ketogenic diet-induced modulation of metabolic pathways

Guoyao Wu, Guoyao Wu, R. Aramayo, 2016, Amino Acids.

In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.

M. Zalutsky, P. Welsh, S. Carlin, 2006, Nuclear medicine and biology.

Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

R. Coleman, R. McLendon, A. Friedman, 2007, Journal of Nuclear Medicine.

Production of 99Mo/99mTc via photoneutron reaction using natural molybdenum and enriched 100Mo: part 1, theoretical analysis

G. Akabani, Peter G. Brown, T. M. Martin, 2017, Journal of Radioanalytical and Nuclear Chemistry.

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

Mitchel S Berger, Allan H Friedman, James M Provenzale, 2008, Neuro-oncology.

Preliminary Production of 211At at the Texas A&M University Cyclotron Institute

R. Tribble, G. Akabani, M. Hackemack, 2014, Health physics.

THE SPARSITY-PROMOTED SOLUTION TO THE UNDERSAMPLING TOF-PET IMAGING: NUMERICAL SIMULATIONS

Dapeng Lao, Gamal Akabani, Mark W. Lenox, 2013 .

Low-energy cross-section calculations of single molecules by electron impact: a classical Monte Carlo transport approach with quantum mechanical description

G. Akabani, J. R. Madsen, 2014, Physics in medicine and biology.

Applicability test of methods for discrimination between external and internal contamination using an ORTEC whole body counter.

G. Akabani, T. Kong, H. Kim, 2014, Radiation protection dosimetry.

Molecular imaging of small animals with a triple-head SPECT system using pinhole collimation

Ronald J. Jaszczak, Scott D. Metzler, Bennett B. Chin, 2005, IEEE Transactions on Medical Imaging.

Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.

Michael R Zalutsky, S. Kennel, M. Zalutsky, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.

R. McLendon, D. Bigner, M. Zalutsky, 2002, International journal of radiation oncology, biology, physics.

Feasibility of Whole-Body Functional Mouse Imaging Using Helical Pinhole SPECT

Ronald J. Jaszczak, Bennett B. Chin, Sreekanth Vemulapalli, 2009, Molecular Imaging and Biology.

A Novel Method to Extend a Partial-Body CT for the Reconstruction of Dose to Organs beyond the Scan Range

Choonsik Lee, Choonik Lee, G. Akabani, 2018, Radiation Research.

Long Term Response in a Patient with Neoplastic Meningitis Secondary to Melanoma Treated with 131 I-Radiolabeled Antichondroitin Proteoglycan

A. Friedman, D. Bigner, J. Provenzale, 2001 .